Efficient transformation of previously activated and dividing T lymphocytes by human T cell leukemia-lymphoma virus. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Efficient transformation of previously activated and dividing T lymphocytes by human T cell leukemia-lymphoma virus.

Blood. 1984 Nov;64(5):967-74. Unique Identifier : AIDSLINE MED/85023732
Merl S; Kloster B; Moore J; Hubbell C; Tomar R; Davey F; Kalinowski D; Planas A; Ehrlich G; Clark D; et al


Abstract: Modifying previously reported techniques, we attempted to increase the efficiency of human T cell leukemia-lymphoma virus (HTLV) transformation of human T lymphocytes. Lethally irradiated donor cells (DCs) were cultured with target mononuclear cells (TMCs). DCs included ten HTLV+ T cell lines with varying degrees of virus expression or seven cell lines that do not express HTLV. TMCs were prepared from 20 cord and 16 adult peripheral blood samples, including eight patients with acquired immunodeficiency syndrome (AIDS). TMCs were either added directly to the DCs or were first stimulated with phytohemagglutinin (PHA) (5 micrograms/mL) and grown in T cell growth factor (TCGF) prior to exposure to DCs. The presence of integrated HTLV proviral DNA in the transformed cells was determined by dot blot hybridization, utilizing a cloned probe to the HTLV-I genome. HTLV production by transformed TMCs was assessed for HTLV p19, reverse transcriptase, and virus particles. No transformation occurred with T cell donor lines that do not express HTLV. Low virus expressor DCs could only, with rare exception, transform preactivated TMCs. High-titer virus-producing DCs could transform activated and nonactivated cord blood cells and activated adult TMCs. Only MT-2 could routinely transform nonactivated normal adult and activated AIDS TMCs. HUT 102 B2 could transform only one activated AIDS sample, the cells of which initially expressed HTLV-like proteins and virions. Transformed cell lines contained subsets of mature T lymphocytes with variable HTLV expression. Prior activation and culture of the T lymphocytes increases the probability and rate of transformation by HTLV, allowing for biologic detection of low HTLV-producing cells and for in vitro expansion of T lymphocyte subsets from selected patients.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Antibodies, Monoclonal/IMMUNOLOGY Antigens, Surface/IMMUNOLOGY Cell Line *Cell Transformation, Neoplastic Cells, Cultured Human Mitosis Retroviridae/PHYSIOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, Non-P.H.S. T-Lymphocytes/*IMMUNOLOGY/PHYSIOLOGY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/immunologyantibodies,monoclonal/immunologyantigens,surface/immunologycelllineKWDcelltransformation,neoplasticcells,culturedhumanmitosisretroviridae/physiologysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,non-pKWDhKWDsKWDt-lymphocytes/KWDimmunology/physiologyjournalarticle
850228
M8520091


Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .